Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of Bemnifosbuvir/Ruzasvir FDC in Healthy Subjects
NCT06204679Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Dec 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bemnifosbuvir and ruzasvir in hepatitis C (HCV) (3 arms), sponsored by Atea Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at Day 13, Area Under the Curve at Day 13 and 2 more. Started Dec 2023; status: completed.
02
Drugs
bemnifosbuvirruzasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT06204679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06204679.